Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Rigel Pharmaceuticals 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 USA

www.rigel.com Employees: 164 P: 650-624-1100 F: 650-624-1101

Sector:

Medical

Description:

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

Key Statistics

Overview:

Market Capitalization, $K 798,825
Enterprise Value, $K 794,485
Shares Outstanding, K 18,151
Annual Sales, $ 179,280 K
Annual Net Income, $ 17,490 K
Last Quarter Sales, $ 69,460 K
Last Quarter Net Income, $ 27,900 K
EBIT, $ 118,950 K
EBITDA, $ 120,470 K
60-Month Beta 1.11
% of Insider Shareholders 9.48%
% of Institutional Shareholders 66.23%
Float, K 16,430
% Float 90.52%
Short Interest 2,758
Short Float 15.19%
Short Volume Ratio 0.35

Growth:

1-Year Return 154.98%
3-Year Return 193.40%
5-Year Return 25.74%
5-Year Revenue Growth 202.38%
5-Year Earnings Growth 124.75%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.46 on 11/04/25
Next Earnings Date 03/03/26
Earnings Per Share ttm 6.17
EPS Growth vs. Prev Qtr -55.49%
EPS Growth vs. Prev Year 108.57%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/27/24

RIGL Ratios

Ratio
Price/Earnings ttm 7.24
Price/Earnings forward 6.83
Price/Earnings to Growth N/A
Return-on-Equity % 204.70%
Return-on-Assets % 57.42%
Profit Margin % 9.76%
Debt/Equity 0.25
Price/Sales 4.52
Price/Cash Flow 41.38
Price/Book 6.89
Book Value/Share 6.48
Interest Coverage 3.32
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar